Tvardi raises $13.3M in stock sale as cash runway shrinks to 2027
What's the deal? Clinical-stage biopharma Tvardi Therapeutics raised $13.3 million in gross proceeds through an at-the-market (ATM) equity offering in the third quarter, selling about 3.96 million shares, according to its Form 10-Q filed November 13. The Houston-based company reported a Q3 net loss of $6.1 million, up from $5.5 million a year earlier.
What's the endgame? Tvardi develops oral STAT3-targeting therapies for inflammatory and proliferative diseases. Its lead program, TTI-101 for liver cancer, is due to deliver topline data early in the first quarter of 2027 — a readout chief executive officer Imran Alibhai said "will help inform our next steps."
By the numbers: Cash and equivalents stood at $22.3 million as of September 30, down from $30.8 million at year-end 2025. The nine-month net loss widened to $19.4 million from $10.9 million. Roughly $7.4 million remains under the ATM facility, against a $200 million shelf.
Why now? The company disclosed going-concern doubt, saying its capital will fund operations only into the third quarter of 2027. Advancing its second program, TTI-109 in ulcerative colitis, depends on additional funding and IND clearance, neither of which is secured.
What could go wrong? The $13.3 million raise bought time but diluted holders, lifting shares outstanding from 9.4 million to 13.3 million. An earlier TTI-101 study in pulmonary fibrosis missed its goals, raising the stakes on the coming liver-cancer data.
The signal: For a cash-constrained biotech, the financing matters less than the dilution it brings and the fact that key development steps remain funding-dependent. The 2027 liver-cancer readout now stands as the catalyst that determines whether investors back further development.
Read more: kalkinemedia.com
Image credit: Generated with Gemini